Get the Stockscreener App
19.97
1.11%
0.22
After Hours:
20.40
0.43
+2.15%
Bausch Lomb Corp stock is traded at $19.97, with a volume of 120.22K.
It is up +1.11% in the last 24 hours and down -2.39% over the past month.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
See More
Previous Close:
$19.75
Open:
$19.73
24h Volume:
120.22K
Relative Volume:
0.19
Market Cap:
$6.96B
Revenue:
$4.68B
Net Income/Loss:
$-368.00M
P/E Ratio:
-33.68
EPS:
-0.5929
Net Cash Flow:
$-58.00M
1W Performance:
+3.04%
1M Performance:
-2.39%
6M Performance:
+32.96%
1Y Performance:
+31.30%
1-Day Range:
$19.72
$20.05
1-Week Range:
$19.32
$20.05
52-Week Range:
$13.16
$21.69
Bausch Lomb Corp Stock (BLCO) Company Profile
Name
Bausch Lomb Corp
Sector
Industry
Phone
908-541-5456
Address
520 APPLEWOOD CRESCENT, VAUGHAN
Compare BLCO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLCO
Bausch Lomb Corp
|
19.97 | 6.96B | 4.68B | -368.00M | -58.00M | -0.5929 |
|
ISRG
Intuitive Surgical Inc
|
538.55 | 192.83B | 7.87B | 2.24B | 586.00M | 4.25 |
|
BDX
Becton Dickinson Co
|
221.98 | 64.77B | 20.18B | 1.73B | 3.07B | 5.51 |
|
ALC
Alcon Inc
|
88.23 | 43.75B | 9.76B | 1.16B | 665.00M | 0.72 |
|
RMD
Resmed Inc
|
249.33 | 36.84B | 4.81B | 1.11B | 1.35B | 6.16 |
|
WST
West Pharmaceutical Services Inc
|
323.32 | 23.33B | 2.88B | 499.60M | 321.60M | 7.41 |
Bausch Lomb Corp Stock (BLCO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-15-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-10-24 | Initiated | Raymond James | Outperform |
| May-06-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-04-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Dec-12-23 | Initiated | Stifel | Hold |
| Oct-03-23 | Resumed | Evercore ISI | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Mar-09-23 | Initiated | Needham | Hold |
| Dec-21-22 | Initiated | Barclays | Equal Weight |
| Sep-12-22 | Initiated | H.C. Wainwright | Buy |
| Jul-26-22 | Initiated | RBC Capital Mkts | Outperform |
| Jun-24-22 | Initiated | Evercore ISI | Outperform |
| Jun-06-22 | Initiated | Citigroup | Buy |
| May-31-22 | Initiated | Deutsche Bank | Hold |
| May-31-22 | Initiated | Goldman | Neutral |
| May-31-22 | Initiated | Guggenheim | Buy |
| May-31-22 | Initiated | JP Morgan | Neutral |
| May-31-22 | Initiated | Jefferies | Buy |
| May-31-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-31-22 | Initiated | Wells Fargo | Overweight |
| May-11-22 | Initiated | Cowen | Outperform |
View All
Bausch Lomb Corp Stock (BLCO) Latest News
Bausch & Lomb Corporation (BLCO)-A Bull Case Theory - Insider Monkey
Bausch + Lomb Co. (NYSE:BLCO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Bausch + Lomb Reports More Than 94 Million Units of Contact Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs - Business Wire
Bausch + Lomb (BLCO) Posts Impressive Revenue and Explores Potential Sale - Nasdaq
Bausch & Lomb Secures $400 Million in New Term Loans - Investing.com India
Bausch & Lomb Secures $400 Million in New Term Loans By Investing.com - Investing.com South Africa
Bausch + Lomb Corporation (NYSE:BLCO) Q3 2024 Earnings Call Transcript - Insider Monkey
Bausch & Lomb stock target lifted, keeps buy on strong Q3 results - Investing.com
Bausch + Lomb (BLCO) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Bausch + Lomb (BLCO) Q3 Earnings and Revenues Top Estimates - Yahoo Finance
Orthokeratology Lens Market is expected to Double Its Size - openPR
Bausch + Lomb posts top-line beat, raises full-year outlook - Investing.com
Bausch + Lomb: Q3 Earnings Snapshot - Marketscreener.com
Bausch + Lomb Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bausch + Lomb Announces Third-Quarter 2024 Results - Business Wire
Bausch & Lomb Corp (TSX:BLCO) Q3 2024 Earnings Report Preview: W - GuruFocus.com
BAUSCH & LOMB CORP (BLCO)Sunday, Jul 28, 2024 - Smartkarma
Warburg Pincus completes acquisition of B&L for $4.5 bln - Reuters
Dry Eye Treatment Market to Hit $9.3 Billion: Bausch + Lomb Acquires XIIDRA, New FDA Approvals Boost Options - openPR
Bausch + Lomb price target raised to $23 from $20 at RBC Capital - Yahoo Finance
Bausch + Lomb (BLCO) Set to Announce Quarterly Earnings on Wednesday - MarketBeat
RBC raises Bausch & Lomb stock price target ahead of Q3 results - Investing.com Canada
Bausch + Lomb (NYSE:BLCO) PT Raised to $23.00 - MarketBeat
Banks, Private Credit Vie for $5 Billion Bausch + Lomb Debt - Bloomberg
Deal Dispatch: Altus Power, Motorsport Games Explore Options, True Value Goes Bankrupt, M&A Activity Lags - Benzinga
Bausch & Lomb gains amid report TPG, Blackstone working on joint bid - MSN
Banks, Private Credit Vie for $5 Billion Bausch Lomb Financing | Today News - Mint
Exclusive | Bausch Health Rejects Bondholders’ Debt Proposals, Explores Sale of Vision Care Unit - The Wall Street Journal
Bausch & Lomb shares upgraded, price target raised By Investing.com - Investing.com UK
NVIDIA, Trump Media & Technology, Bausch + Lomb, Sirius XM And Other Big Stocks Moving Higher On Monday - MSN
Bausch + Lomb Corp [BLCO] Investment Guide: What You Need to Know - Knox Daily
Bausch Lomb Shows Rising Price Performance With Jump To 91 RS Rating - Investor's Business Daily
Why Bausch + Lomb Stock Soared by Over 7% on Monday - Yahoo Finance
TPG and Blackstone team up to bid for eyecare group Bausch + Lomb - Financial Times
Anthony Wallace of Bausch + Lomb talks about enVista Envy FDA approval - Ophthalmology Times
Bausch + Lomb wins FDA nod for enVista Envy range of intraocular lenses - Medical Device Network
Bausch + Lomb Stock Pops as TPG, Blackstone Consider Joint Bid - Yahoo Finance
Bausch + Lomb (NYSE:BLCO) Sets New 1-Year HighHere's What Happened - MarketBeat
Bausch + Lomb stock hits 52-week high at $21.19 amid robust growth - Investing.com UK
S&P 500 Futures Rise in Premarket Trading; Bausch + Lomb, MicroStrategy Lead - Barron's
Bausch + Lomb Receives FDA Approval for enVista® Envy™ Full Range of Vision Intraocular Lens - Business Wire
Bausch Lomb Clears Technical Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: Bausch + Lomb Corp (BLCO) - SETE News
Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30 - Business Wire
Marshall Wace LLP Takes $1.91 Million Position in Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Bausch + Lomb eyes new ecommerce opportunity - Digital Commerce 360
Bausch + Lomb price target raised to $19 from $17 at Evercore ISI - Yahoo Finance
Bausch + Lomb Launches Opal™ Digital Marketplace in the United States - Business Wire
Clearline Capital LP Acquires 411,404 Shares of Bausch + Lomb Co. (NYSE:BLCO) - MarketBeat
Wall Street SWOT: Bausch + Lomb stock rides wave of eye health innovation - Investing.com
Bausch Lomb Corp Stock (BLCO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):